Learning from the Extension of Biomet’s DPA

Days before its March 2012 deferred prosecution agreement was about to expire, medical device manufacturer Biomet announced that the DOJ was extending the term of its agreement for another year amidst allegations of further bribery in Mexico and Brazil.  Biomet, whose $13.35 billion merger with Zimmer Holdings is imminent, reportedly discovered the new bribery allegations (some of which involve offshoots of the original culpable distributors) through an anonymous whistleblower report.  FCPA experts share their insights on Biomet’s troubles and the DOJ’s tactics.  See also “Weak FCPA Compliance Program and Lack of Cooperation Cited in Marubeni’s $88 Million Guilty Plea,” The FCPA Report, Vol. 3, No. 7 (Apr. 2, 2014).

To read the full article

Continue reading your article with an ACR subscription.